NCT04428411View on ClinicalTrials.gov

Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).

CompletedOBSERVATIONAL
Enrollment

486

Participants

Timeline

Start Date

July 5, 2020

Primary Completion Date

August 30, 2020

Study Completion Date

August 30, 2020

Conditions
Plaque Psoriasis
Interventions
DRUG

Enbrel

As provided in real world practice

Trial Locations (1)

Unknown

Pfizer, Baghdad

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04428411 - Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO). | Biotech Hunter | Biotech Hunter